[A study on the clinical efficacy of a combination regimen with levofloxacin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis].
OBJECTIVE
To study the clinical efficacy of a combination therapy with levofloxacin (LVFX), capreomycin (CPM) and other second-line antituberculosis drugs in the treatment of multi-drug resistant pulmonary tuberculosis (MDR-TB).


METHODS
177 patients with MDR-TB were assigned to a study group (88 cases), treated with LVFX, CPM, pyrazinamide (PZA), rifapentine (RFT) and pasiniazid (PSZ); or a control group, treated with streptomycin (SM), ethambutol (EMB), PZA, RFT and PSZ. The course of treatment was 21 months.


RESULTS
82 cases in the study group and 79 cases in the control group completed the treatment. The sputum negative conversion rate in the study group (83%) was significantly higher than that in the control group (58%) (P < 0.01). The radiographic improvement rate was 50% in the study group, significantly higher than that in the control group (28%) (P < 0.01). The closure rate of the lung cavities in the study group (63%) was higher than that in the control group (42%) (P < 0.05). No significant difference was found in side-effects between the two groups (31% in the study group, and 35% in the control group respectively) (P > 0.05).


CONCLUSIONS
The regimen including LEVX, CPM and other second-line anti-TB drugs was effective and safe for patients with MDR-TB.
D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002207:Capreomycin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage; D011718:Pyrazinamide / Q000008:administration & dosage; D012293:Rifampin / Q000008:administration & dosage; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D002207:Capreomycin; D011718:Pyrazinamide; D064704:Levofloxacin; D015242:Ofloxacin; D012293:Rifampin